Please login to the form below

Not currently logged in
Email:
Password:

EC expands Janssen’s prostate cancer drug reach

Zytiga plus predinson/prednisolone will now treat mHSPC patients

JanssenJanssen has chalked up a significant win in the European market following a ruling on its prostate cancer drug Zytiga (abiraterone acetate), receiving the go-ahead to add an earlier stage of metastatic prostate cancer to the drug’s label.

Initially the once daily oral drug was approved in combination with predinson/prednisolone for the treatment of metastatic castration-resistance prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of ADT and in patients where chemotherapy is not yet clinically indicated.

It was also originally approved for the same indication but in patients whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

However, the European Commission’s decision has extended Zytiga’s indication to include the treatment of newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).

Dr Ivo Winiger-Candolfi, oncology solid tumour therapy area lead, Janssen EMEA, said: “This EC approval is a major step forward for men living with prostate cancer across Europe and offers patients with newly-diagnosed high-risk mHSPC a new treatment option.”

Prostate cancer is the most common form of cancer in men throughout Europe and according to the Johnson and Johnson pharma group, patients with mHSPC, particularly with high-risk characteristics, have a poor prognosis.

Dr Winiger-Candolfi added: “We are encouraged by the data we have seen to date and remain committed to transforming outcomes for prostate cancer patients.

The approval from the EU regulators follows a recommendation from the Committee for Medical Products for Human Use (CHMP), which was based on the positive results of Janssen’s LATITUDE study.

Article by
Gemma Jones

23rd November 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics